Health Care & Life Sciences » Biotechnology | Theravance Biopharma Inc.

Theravance Biopharma Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
156,284.00
237,038.00
182,219.00
190,669.00
285,405.00
215,524
Depreciation, Depletion & Amortization
2,653.00
2,662.00
2,500.00
2,200.00
4,027.00
3,166
Other Funds
123,593.00
370,799.00
75.00
21.00
-
40,062
Funds from Operations
131,135.00
187,925.00
131,074.00
145,917.00
223,483.00
172,296
Changes in Working Capital
10,176.00
12,770.00
37,783.00
46,928.00
22,431.00
59,429
Net Operating Cash Flow
120,959.00
175,155.00
168,857.00
98,989.00
201,052.00
112,867
Capital Expenditures
2,734.00
3,107.00
2,647.00
2,135.00
2,406.00
Purchase/Sale of Investments
-
103,284.00
113,686.00
146,100.00
53,927.00
Net Investing Cash Flow
2,634.00
106,251.00
111,039.00
148,235.00
56,333.00
Issuance/Reduction of Debt, Net
-
-
-
222,498.00
-
Net Financing Cash Flow
123,593.00
370,621.00
81,310.00
479,226.00
1,656.00
Net Change in Cash
-
89,215.00
23,492.00
232,002.00
255,729.00
Free Cash Flow
123,693.00
178,262.00
171,504.00
101,124.00
203,458.00
Other Sources
100.00
140.00
-
-
-
Change in Capital Stock
-
178.00
81,385.00
256,707.00
1,656.00

About Theravance Biopharma

View Profile
Address
Ugland House
George Town GT KY1
Cayman Islands
Employees -
Website http://www.theravance.com
Updated 07/08/2019
Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.